Dublin, Ireland
Dublin, Ireland
SEARCH FILTERS
Time filter
Source Type

Yoo J.W.,University of Wisconsin - Madison | Yoo J.W.,ACE Health | Kim S.,Case Western Reserve University | Kim S.J.,Yonsei University | And 6 more authors.
Journal of the American Pharmacists Association | Year: 2013

Objective: To explore whether racial disparity in osteoporosis drug therapy maintenance varies by health insurance coverage status. Design: Longitudinal observation study. Setting: Cleveland Clinic Health System (Cleveland, OH) from January 2006 to December 2009. Patients: 3,901 black and white female Medicare beneficiaries starting osteoporosis drug therapy. Intervention: Analysis of the health system's integrated electronic medical records. Main outcome measures: Drug therapy adherence (medication possession ratio ≥80%) for more than 12 of 15 surveillance units and occurrence of extended nonadherence gaps for at least two surveillance units in a row. Results: Among patients with supplementary health insurance (n = 2,278), no difference was observed for drug therapy adherence (P = 0.17) and extended nonadherence gaps (P = 0.53) between black and white participants. When patients did not have supplementary health insurance (n = 1,623), blacks (36% [95% CI 28-47]) were less likely to adhere to drug therapy than whites (47% [38-57]; odds ratio [OR] 0.34 [95% CI 0.09-0.92], P = 0.004). Blacks (25% [19-32]) also were more likely to have an extended nonadherence gap episode than whites (18% [11-26]; OR 2.42 [1.13-3.50], P = 0.03). Conclusion: Similar to previous research on racial disparity in health services, racial disparity in osteoporosis drug therapy maintenance between black and white female older patients existed when supplementary health insurance was not affordable.


Saxena P.,ACE Health | Chen G.,ACE Health | Jideh B.,ACE Health | Collins G.,ACE Health | Leong R.W.,ACE Health
Expert Opinion on Biological Therapy | Year: 2014

Background: Infliximab is recommended to be infused over 2 h, but accelerated infusion rates of 30 min may improve efficiency, patient satisfaction and reduce nursing time and cost. The safety of this approach is not established. This study aims to assess the safety of accelerated infliximab infusion and determine the direct cost savings. Methods: The primary endpoint of the study was adverse events and the secondary endpoints were cost, time saving per infusion and patient satisfaction associated with an accelerated infusion protocol. Results: One hundred and thirty-six and 342 infusions were administered to 23 and 39 patients in the standard and accelerated protocols, respectively (mean infusion times 150 and 73.4 min, respectively, p < 0.0001). The adverse reaction rate of the standard protocol was 2.2% (95% confidence interval: 0.46-6.57) and accelerated protocol was 3.2% (95% CI: 1.74-5.73; p = 0.77). The odds ratio of adverse reaction for the 30-min infusion was 0.40 (95% CI: 0.09-1.82). The relative direct cost of nursing was decreased by 51.1% per infusion. Patient satisfaction score of the accelerated protocol was 9.2/10 (95% CI: 8.55-9.76) compared to 8.5/10 (95% CI: 7.83-9.17) in the initiation phase (p = 0.018). Conclusions: Accelerated 30-min infliximab infusions significantly reduced nursing time, cost and increased patient satisfaction without increasing infusion reactions. Increased patient freedom and improved efficiency in healthcare delivery can be expected. © 2014 Informa UK, Ltd.


ACE Health | Entity website

Trinity Technology & Enterprise Campus,Pearse St, Dublin 2, Ireland 2016 GroupNos Technologies Ltd


ACE Health | Entity website

Trinity Technology & Enterprise Campus,Pearse St, Dublin 2, Ireland 2016 GroupNos Technologies Ltd


ACE Health | Entity website

Trinity Technology & Enterprise Campus,Pearse St, Dublin 2, Ireland 2016 GroupNos Technologies Ltd


ACE Health | Entity website

Trinity Technology & Enterprise Campus,Pearse St, Dublin 2, Ireland 2016 GroupNos Technologies Ltd


ACE Health | Entity website

Trinity Technology & Enterprise Campus,Pearse St, Dublin 2, Ireland 2016 GroupNos Technologies Ltd


ACE Health | Entity website

Trinity Technology & Enterprise Campus,Pearse St, Dublin 2, Ireland 2016 GroupNos Technologies Ltd


News Article | February 18, 2014
Site: www.centerforclinicalexcellence.com

Be a member of the fastest growing online clinical community for mental health and behavioral health clinicians in the world. Required fields are marked with Thank you for your interest in the International Center for Clinical Excellence. You will receive an email with a confirmation link to join the site (if it does not arrive please check your Spam folder).

Loading ACE Health collaborators
Loading ACE Health collaborators